Halozyme Therapeutics (Nasdaq: HALO) today announced a global collaboration and non-exclusive license agreement with fellow US biotech Acumen Pharmaceuticals (Nasdaq: ABOS), following which the former’s shares dipped 1.2% to $35.62 and Acumen’s stock fell 1.1% to $2.14.
The deal will provide Acumen with access to Halozyme's Enhanze drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target.
Acumen intends to explore the potential use of Enhanze for ACU193, Acumen's clinical-stage monoclonal antibody (MAb) candidate to target amyloid-β oligomers (AβOs) for the treatment of early Alzheimer's disease (AD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze